Abstract:Background: Recently, several studies have suggested that abnormal quantity and function of regulatory T cells (Tregs) may play a vital role in the development of rheumatoid arthritis (RA). CD25+FOXP3+ T cells include CD4+ (CD4+ Tregs) and CD8+ cells (CD8+ Tregs). Recently studies have shown that CD8+ Tregs also have immunosuppressive function, similar to even stronger than CD4+ Tregs, and are more sensitive to IL-2 in vivo. However, the status of CD8+Treg cells in RA is unknown. Objectives: Our study was designed to clarify the level of CD4-CD25+FOXP3+ T cells in RA patients, and to investigate the role of low-dose interleukin-2 (IL-2) therapy in the regulation of CD4-CD25+FOXP3+ T cells in RA patients to provide another theoretical basis besides CD4+ Tregs to IL-2 therapy. Methods: Three hundred and four RA patients (diagnosis according to the 2010 ACR criteria) were enrolled; no treatment group (N = 75), DMARDs treatment group (N = 73), low dose IL-2 treatment group (50WIU/day × 5 days, subcutaneous injection) (N = 156), and healthy control group (N = 90). The absolute numbers of CD4-CD25+FOXP3+ T cells in peripheral blood were detected by flow cytometry. We assumed that CD4- T cells with CD25+ and FOXP3+ were mostly CD8+CD25+FOXP3+ Treg cells, which was CD4-CD25+FOXP3+ T cells in this study. The levels of CD4-CD25+FOXP3+ T cells among these groups were compared with that of health group or each other respectively, and then the statistical software SPSS 20.0 was used for analysis; p<0.05 was considered significant. Results: As compared with the healthy group, the absolute number of CD4-CD25+FOXP3+ T cells decreased significantly in the untreated RA patients [0.94(0.41,1.61) vs 1.31(0.72,2.52), P<0.001] and more dramatically in DMARDs treatment patients [0.86(0.36,1.83) vs 1.31(0.72,2.52), P<0.01]. After treatment with IL-2, the absolute count of CD4-CD25+FOXP3+ T cells increased significantly compared with that before treatment [0.91(0.48,1.54) vs 2.10(1.12,3.56), P<0.001]. Conclusions: The absolute number of CD4-CD25+FOXP3+ T cells in untreated RA patients were lower than those health, implying that CD4-CD25+FOXP3+ T cells deficiency was caused by disease itself but not immunosuppressive therapy, which may be an important factor in the pathogenesis of RA. The traditional DMARDs therapy did not improve this reduction. Low dose IL-2 can increase the absolute number of CD4-CD25+FOXP3+ T cells in peripheral blood. We are about to detect the number of CD8+CD25+FOXP3+ Treg cells accurately to verify this theory. Disclosure of Interest: None declared

Invariant Natural Killer T Cells Regulate Conventional Dendritic Cell Maturation to Re-establish Immune Tolerance to Rheumatoid Arthritis in DBA/1 Mice

Early activation of invariant natural killer T cells in a rheumatoid arthritis model and application to disease treatment

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

SAT0213 Low Dose Il-2 Restores Decreased Absolute Number of Regulatory T Cells and Imbalance Between Th17 and Regulatory T Cells in Patients with Rheumatoid Arthritis

Natural Killer Cell Degeneration Exacerbates Experimental Arthritis in Mice Via Enhanced Interleukin-17 Production.

Antigen-specific transforming growth factor β-induced Treg cells, but not natural Treg cells, ameliorate autoimmune arthritis in mice by shifting the Th17/Treg cell balance from Th17 predominance to Treg cell predominance.

SAT0163 Absolute Number of Peripheral Cd4-Cd25+foxp3+t Cells Decreases and Restores after Low-Dose Interleukin-2 Treatment in Rheumatoid Arthritis

Inflammatory Cytokine-Neutralizing Antibody Treatment Prevented Increases in Follicular Helper T Cells and Follicular Regulatory T Cells in a Mouse Model of Arthritis.

IFN-β Pretreatment Alleviates Allogeneic Renal Tubular Epithelial Cell–Induced NK Cell Responses Via the IRF7/HLA-E/NKG2A Axis

IFN-β Pretreatment Alleviates Allogeneic Renal Tubular Epithelial Cell-Induced NK Cell Responses via the IRF7/HLA-E/NKG2A Axis.

Natural Killer Cells Modulate Overt Autoimmunity to Homeostasis in Nonobese Diabetic Mice after Anti-CD3 F(ab′)2 Antibody Treatment through Secreting Transforming Growth Factor-β

Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity

Atra Restores the Stability and Functionality of Ntregs in the Inflammatory Milieu

Targeting Kinase ITK Treats Autoimmune Arthritis Via Orchestrating T Cell Differentiation and Function

Natural killer-like B cells promote Th17 cell differentiation and exacerbate rheumatoid arthritis

A Mouse Model of Adoptive Immunotherapeutic Targeting of Autoimmune Arthritis Using Allo-Tolerogenic Dendritic Cells.

Treg-targeted efficient-inducible platform for collagen-induced arthritis treatment

Ligand-Dependent Induction of Noninflammatory Dendritic Cells by Anergic Invariant Nkt Cells Minimizes Autoimmune Inflammation

TGF-β-induced CD4+ Regulatory T Cells but Not Ntregs Ameliorate Autoimmune Arthritis by Shifting the Balance Between Tregs and Th17 Cells in Vivo (179.14)

Adoptive Induced Antigen-Specific Treg Cells Reverse Inflammation in Collagen-Induced Arthritis Mouse Model

Mechanism of PD-1/PD-L1 in Regulating cTfr/cTfh Balance in Patients with Rheumatoid Arthritis